Diagnosis: Stevens-Johnson syndrome / toxic epidermolysis necrolysis spectrum
A 34-year-old male presented with painful mucositis and extensive skin sloughing following the initiation of a new medication for hypertension. Examination revealed erythematous macules and bullae involving over 30% of the body surface area, including mucosal involvement. This case highlights the critical need for vigilance in recognizing severe cutaneous adverse drug reactions.
A 34-year-old male presented to the emergency department with a 5-day history of painful mucositis and widespread skin detachment after starting a new antihypertensive medication. On examination, he exhibited significant erythematous macules and bullae, with areas of denuded skin covering approximately 30% of his body surface area, including severe mucosal involvement affecting the oral cavity and genital region.Extensive epidermal detachment with erythematous macules and bullae on trunk and extremities.Mucosal involvement with painful lesions in the oral cavity and conjunctiva.Systemic symptoms including fever and malaise.Positive Nikolsky sign on examination.Rapid progression of skin lesions over 48 hours.
The patient reported that the onset of symptoms began 5 days after starting a new medication for hypertension. He had no previous history of drug allergies and had not experienced similar reactions in the past. His past medical history was notable for well-controlled hypertension, and he denied any recent infections or changes in lifestyle. Family history was unremarkable for dermatologic conditions. He was a non-smoker and reported occasional alcohol use.Onset: Symptoms began 5 days after initiating a new antihypertensive medication.Triggers: Recent introduction of medication with no prior history of drug reactions.Past medical history: Well-controlled hypertension, no prior drug allergies.Social history: Non-smoker, occasional alcohol use.Family history: No significant dermatologic conditions.
Acute / First-Line ManagementImmediate discontinuation of the offending medication.Supportive care including fluid resuscitation and electrolyte management.Administration of systemic corticosteroids (e.g., prednisone 1 mg/kg/day) for severe cases to reduce inflammation.Consideration of intravenous immunoglobulin (IVIG) at a dose of 1 g/kg for severe cases, though evidence is variable.Workup and Diagnostic ConfirmationClinical diagnosis based on history and physical examination, with emphasis on the time course of drug exposure.Skin biopsy may be performed to assess for full-thickness epidermal necrosis.Laboratory tests to evaluate for potential infectious etiologies and electrolyte imbalances.Consultation with dermatology and supportive care specialists for comprehensive management.Long-Term ManagementRegular follow-up to monitor for complications, including secondary infections.Skin care with emollients to promote healing and prevent dryness.Education on avoiding known drug triggers in the future.Psychological support for potential post-traumatic stress related to the acute event.
Acute Generalized Exanthematous Pustulosis (AGEP): Characterized by the rapid onset of pustular lesions, typically within days of drug exposure, often with fever and leukocytosis.Dermatitis Herpetiformis: Presents with pruritic vesicular lesions, often on extensor surfaces, and is associated with celiac disease; biopsy shows granular IgA deposits.Fixed Drug Eruption: Localized lesions that recur at the same site upon re-exposure to the offending agent, often with a characteristic morphology.Drug-Induced Hypersensitivity Syndrome (DIHS): Features fever, lymphadenopathy, and multiorgan involvement, often with eosinophilia; occurs 2-8 weeks after drug exposure.Viral Exanthems: Often accompanied by systemic symptoms such as fever; history of recent viral infection is key for differentiation.Infectious Bullous Diseases: Such as pemphigus vulgaris and bullous pemphigoid; typically have a more chronic course and distinct clinical features.Contact Dermatitis: Localized rash due to allergen exposure; history of exposure and morphology can aid in differentiation.Psoriasis: Plaque psoriasis can present with erythematous plaques and scaling, but lacks mucosal involvement and rapid progression seen in severe reactions.
High-Yield PearlsRecognition: Early identification of severe cutaneous adverse drug reactions is crucial for improving patient outcomes.Timing: The onset of symptoms within days of drug exposure can help differentiate from other dermatologic conditions.Supportive Care: Comprehensive supportive care is essential, including fluid management and pain control.Corticosteroids: Systemic corticosteroids are the mainstay of treatment for severe cases but should be used judiciously.Education: Patient education on drug avoidance and recognition of early symptoms can prevent future reactions.Severe cutaneous adverse drug reactions require prompt recognition and intervention to mitigate morbidity and mortality.
Tags: SJS, TEN, drug reaction